Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with High and Very High Cardiovascular Risk, Including the Presence of Long-COVID Syndrome.

NCT05943821 is registered in ClinicalTrials.gov with Poznan University of Medical Sciences as lead sponsor.

NCT NCT05943821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05943821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with High and Very High Cardiovascular Risk, Including the Presence of Long-COVID Syndrome.
Lead sponsor
Poznan University of Medical Sciences
Phase
Phase 3
Overall status
Recruiting
Start date
September 1, 2023
Completion date
July 31, 2028
Enrollment
1,116 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, uric acid